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17α-hydroxylase-C17,20-lyase (P45017α) is a key regulator enzyme of the steroid hormone biosynthesis in 
both the adrenals and the testes. inhibition of this enzyme can block androgen synthesis in an early step, 
and may thereby be useful in the treatment of several androgen-dependent diseases. We developed radio-
substrate in vitro incubation methods for the determination of the distinct 17α-hydroxylase and C17,20-
lyase activities of the enzyme using rat testicular homogenate as enzyme source. With this method we 
have studied the inhibiting activity of selected steroidal picolyl and picolinylidene compounds. tests 
revealed a substantial inhibitory action of the 17-picolinyliden-androst-4-en-3-one compound.
 
Keywords: EC 1.14.99.9 / EC 4.1.2.30 – 17α-hydroxylase-C17,20-lyase (P45017α) inhibitors – exo-hetero-
cyclic steroids – rat testis – abiraterone
introDuCtion
17α-hydroxylase-C17,20-lyase (P45017α) plays an important role in the pathways of 
steroid hormone biosynthesis [26, 28]. this is a cytochrome P450 enzyme located on 
the endoplasmic reticulum of the cells. It is expressed and active in the adrenal 
glands, testes, ovaries and placenta, primarily. the P45017α is capable of catalysing 
two reactions engaged on a single active site and is active both in the Δ5 and Δ4 path-
ways. the enzyme converts C21 precursors pregnenolone and progesterone (Prog) 
first to their 17α-hydroxy derivatives 17-hydroxypregnenolone and 17-hydroxy-pro-
gesterone (17ohProg). a subsequent side chain cleavage process forms C19 steroids, 
dehydroepiandrosterone (Dhea) and androstenedione (4-en-dione) (fig. 1). Prog is 
a precursor of mineralocorticoids, whereas its hydroxylated derivative 17OHProg 
may result in glucocorticoids. C19 steroids are androgen prehormones: in steroido-
* Corresponding author; e-mail: szecsi.mihaly@med.u-szeged.hu
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genic tissues and target organs they can be further metabolized to more potent andro-
gens such as testosterone and dihydrotestosterone. inhibition of P45017α can block 
androgen synthesis, and may be competent in pharmacological treatment of hormone 
dependent disorders [4, 16, 18]. this enzyme is also a potential target for a drug 
designed to treat androgen dependent prostatic carcinoma [12, 27]. inhibitory action 
was found to be related to lone electron pair coordination to the heme iron atom at 
the active site of the enzyme and many steroidal compounds bearing different heter-
oaromatic moieties on ring D of the sterane skeleton were analyzed against P45017α. 
Pyridyl analogues, for example, exhibited highly effective inhibition of the enzyme, 
and abirateron [17-(3-pyridyl)androsta-5,16-dien-3β-ol] is recently introduced into 
medical application [2, 32, 36]. 
We report here radiosubstrate in vitro incubation methods for the specific determi-
nation of 17α-hydroxylase and C17,20-lyase activities. using these methods we have 
studied inhibitory action of selected steroidal 17-picolyl and 17-picolinylidene 
derivatives exerted towards the rat P45017α. earlier publications describe synthesis 
methods and chemical properties of these compounds [7, 14, 25].
Fig. 1. Steroid biotransformations by 17α-hydroxylase-C17,20-lyase (P45017α)
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materials anD methoDs
Steroid standards and other chemicals
radioactive [4-14C]Prog with specific activity (S.A.) of 46 mCi/mmol and 
[1,2,6,7-3h]17oh-Prog, s. a. = 50 Ci/mmol was purchased from the radiochemical 
Centre, amersham international (amersham, uK) and american radiolabeled 
Chemicals (st. louis, mo, usa), respectively. non-radioactive Prog and 17oh-Prog 
and 4-en-dione standards and reference inhibitor ketoconazole were obtained from 
sigma (st. louis, mo, usa) and fluka (buchs, switzerland). abiraterone was pre-
pared with the synthesis method of Potter et al. [33] and was provided by Professor 
Gyula Schneider and Professor János Wölfling (Department of Organic Chemistry, 
university of szeged). other chemicals and solvents with purity of analytical grade 
were purchased from sigma (st. louis, mo, usa).
Preparation of rat testicular homogenates
testicular tissue was obtained from male rats (12-week old, 200–250 g body mass) 
via surgeries under ether anaesthesia. tissue specimens were washed with an iso-
tonic solution of NaCl. 1.0 g pieces of the testicles of five animals were mixed and 
the tissue sample was homogenized with an Ultra-Turrax in 20.0 ml 0.1 M HEPES 
buffer (ph = 7.3) containing 1 mm eDta and 1 mm dithiothreitol. the homogenate 
was centrifuged at 1500 g for 10 min at 4 °C. the supernatant was divided into por-
tions for storage at –70 °C. 
in vitro incubations
17α-hydroxylase: Testis homogenate aliquots containing suitable amount of enzyme 
(equivalent to 10 mg of testicular tissue) were incubated with 1 μM [14C]Prog 
(25,000 dpm) in the presence of 1 mM NADPH in total volume of 200 μl HEPES 
buffer incubation medium (ph = 7.3). [14C]Prog was added to the incubate in 20 μl 
30 v/v% propylene glycol/hePes buffer solution. incubation was carried out at 
37 °C for 20 min in air. the enzymatic reaction was stopped by the addition of ethyl 
acetate and freezing. After extraction, unlabeled carriers of Prog, 17OH-Prog and 
4-en-dione were added to the samples to aid visualization of steroid spots on the 
chromatography plate by ultraviolet light. the three steroids were separated by thin 
layer chromatography (tlC) on Kieselgel-G (merck si 254 f) layers (0.25 mm 
thick) with the solvent system dichloromethane/diisopropyl ether/ethyl acetate 
(75:15:10 v/v). ultraviolet light was used to trace the separated steroids. Prog, 
17oh-Prog and 4-en-dione were found at retention factors 0.67, 0.24 and 0.48, 
respectively. spots were cut out and the radioactivity of the 17oh-Prog and 4-en-
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dione formed, and the Prog remaining was measured by liquid scintillation counting 
(Packard Tri-Carb 2200CA). The 17α-hydroxylase activity was calculated from the 
conversions corrected with recoveries of the 17oh-Prog and 4-en-dione formed and 
expressed in picomoles.
C17,20-lyase: testis homogenate aliquots containing suitable amount of the enzyme 
(equivalent to 30 mg of testicular tissue) were incubated with 1 μM [3h]17oh-Prog 
(300,000 dpm) in the presence of 1 mm naDPh in hePes buffer incubation medi-
um for 20 min at 37 °C. The substrate, in this procedure, was prepared with mix of 
the tritiated tracer and the non-labelled 17oh-Prog, and was added to the incubate 
also in 20 μl 30 v/v% propylene glycol/HEPES buffer solution. Work-up procedures 
of the incubates and isolation of the 4-en-dione product and the substrate 17oh-Prog 
rest were performed as described above. the C17,20-lyase activity was calculated from 
the conversion corrected with recovery of 4-ene-dione formed.
Fig. 2. Concentration dependent inhibition of 17α-hydroxylase and C17,20-lyase activities of the P45017α 
and logit-log transformation with linear regression analysis of inhibition data for the determination of iC50 
values. P: enzymatic conversion in the presence of inhibitor, P0: enzymatic conversion of the control 
incubation in the absence of inhibitor. relative conversion = P/P0, logit(P) = ln[P/(P0 – P)]. iC50 values 
are derived from intercepts on the axis of ln (inhibitor concentration), as 50% inhibition results in logit 
parameter equal to zero
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Inhibitor tests
The inhibitory effect of the new test compounds was investigated at 0.01–50 μM 
concentration interval. They were added to the incubate in dimethylsulfoxide solution 
in a maximal volume of 10 μl. Measurements were performed at least in four to six 
different concentrations and at least two experiments were done with each concentra-
tion. The control experiments were performed without the test substances in every 
incubation series. abiraterone and a non-steroidal compound ketoconazole, known 
potent P45017α inhibitors were used as reference compounds. the inhibitory effects 
of the compounds investigated in our present work are given in terms of iC50 values, 
i.e. the concentration of inhibitor at which the 17α-hydroxylase or C17,20-lyase activ-
ity was decreased to 50%. iC50 results were calculated by linear regression analysis 
following a logit-log transformation of the data (fig. 2), and the standard deviations 
were determined from the fitted lines. Compounds exerting weaker inhibitory effect 
were investigated at 50 µm concentration and relative conversions compared to con-
trol incubates were determined in these cases. Two experiments were performed and 
mean values and standard deviations were calculated.
results
Methodological investigations
The optimum conditions for the measurement of 17α-hydroxylase and C17,20-lyase 
activities in rat testicular homogenate were determined in preliminary experiments. 
enzyme activities were then measured under conditions of linearity with respect to 
enzyme concentration, and incubation time. Conversion of the substrate in non-
inhibited control incubates was set to 10–15%. We achieved similar turnovers and 
optimal conversion rates applying higher enzyme concentration for the rate limiting 
C17,20-lyase reaction than for 17α-hydroxylase activity, under the same incubation 
conditions. In 17α-hydroxylase method we have found that 15–25% of the 17OH-Prog 
product was consecutively converted to 4-en-dione. this rate was independent from 
incubation conditions (time, substrate or enzyme concentrations) as the cleavage 
process takes place without dissociation of 17oh-Prog from the active centre of 
P45017α. Dimethylsulfoxide and propylene glycol were present in the incubates with 
5.0 and 3.0 v/v% concentrations, respectively. these organic solvent contents did not 
reduce the enzyme activities substantially. Procedural loss of the isolation steps was 
determined by regained radioactivity and the recovery was found around 70% for 
Prog, 60% for 17OH-Prog, and 80% for 4-en-dione. Coefficients of variation of 
enzyme activity results in repeated measurements were within ±10%. iC50 parameters 
of references ketoconazole and abiraterone were found 1.86 ± 0.25 μM and 
0.034 ± 0.003 µM for 17α-hydroxylase, and 0.32 ± 0.02 µM and 0.0125 ± 0.0015 µM 
for C17,20-lyase in our P45017α inhibition test, respectively. these reference results are 
in good agreement with values found in the literature [4, 9, 15, 18, 23, 31–32, 34].
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Inhibitiory effect of the new compounds
We investigated three picolyl (1–3) and three picolinylidene (4–6) androstene com-
pounds (Table 1). Picolyl derivatives exerted no significant inhibition either on the 
17α-hydroxylase or the C17,20-lyase activities under our experimental conditions. 
Relative conversions were found between 66–100%. Elimination of the hydroxy 
group and introduction of a double bond in the side chain of the picolinylidene 
derivatives enhanced inhibitory actions. The two 3-hydroxy picolinylidene deriva-
tives displayed moderate effect. iC50 values of the compounds 4 and 5 were found 38 
µM and 48 µM against the 17α-hydroxylase, and 8.2 µM and 14 µM against the 
C17,20-lyase, respectively. results revealed that compound 6, a picolinylidene deriva-
tive bearing 4-ene-3-oxo structure in its steroidal A-ring, is the best inhibitor among 
the tested compounds. for this compound values of iC50 = 5.9 µM for the 17-hydrox-
ylase activity and iC50 = 2.5 µm towards the C17,20-lyase activity were determined.
DisCussion
P45017α lies at the crossroads of steroid hormone biosynthesis. its inhibition reduces 
testosterone production and provides a feasible way for androgen withdrawal therapy. 
In vitro P45017α inhibition test is an essential step in the development of new antian-
drogen pharmacons and it is applied furthermore in toxicology and in screening of 
xenobiotics or endocrine disruptors [11, 21, 29, 40]. 
various laboratory techniques have been developed in the latest decades for the 
investigation of 17α-hydroxylase and C17,20-lyase activities of the P45017α. 
biotransformations are more often monitored via conversion of 3h or 14C labelled 
substrate steroids. following the enzyme reaction labelled product steroids are iso-
lated with chromatography and then quantified by radiometric detection [3, 6, 10–11, 
21–22, 29, 40]. Other versions of the radiosubstrate method use specifically labelled 
substrates. Hydroxylation of the [17α-3h]Prog eliminates a tritiated water molecule 
[30, 39], whereas cleavage of labelled C-17 side chain of 17oh-Prog produce 
labelled acetic acid [19, 23, 24, 28, 30]. in these techniques, enzyme activities, can 
be detected via measurement of labelled water or acetic acid which remains in the 
incubate water phase following an organic extraction. Further incubation techniques 
apply non-labelled substrate steroids. enzyme products in these methods can be 
either isolated by high performance liquid chromatography and detected by ultravio-
let spectrophotometry [20, 34–35] or can be directly quantified by specific immuno-
assays [9]. Technologies based on quantification of radio-labelled steroidal enzyme 
products, nevertheless, are acknowledged superior to other methods in sense of both 
precision and qualitative identification.
Here we report an improved radiosubstrate method for specific determination of 
the 17-hydroxylase and C17,20-lyase activities of P45017α. the newly developed tech-
nique bears numerous advantages compared to our earlier radiosubstrate methodolo-
gies [13, 37–38]. new procedures use small volume incubates, and apply simple and 
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efficient isolation techniques making these methods suitable for rapid and cost effec-
tive estimation of 17-hydroxylase and C17,20-lyase activities and their inhibition by 
test substances.
in this study, steroidal 17-picolyl and 17-picolinylidene derivatives were investi-
gated against 17-hydroxylase and C17,20-lyase activities of P45017α. it has been found 
that the 17-picolinylidene-androstene compounds exerted stronger inhibition than their 
17-picolyl counterparts. 17-Picolinylidene-androstenes bear trigonal C-17 centre, 
whereas this region displays tetrahedral geometry in the 17-picolyl compounds [8]. 
Compounds bearing heterocyclic side chain attached in trigonal geometry to the ster-
oid C-17 are more potent inhibitors, in general, than those containing tetrahedral C-17 
junction [5]. the rigid planar structure of our 17-picolinylidene groups, in particular, 
stabilizes the nitrogen in a position which is preferred for co-ordination to the heme of 
the enzyme [1]. Double bond at C17-C20 in the 17-picolinylidene compounds extends 
π-electron conjugation of the heterocyclic aromatic ring. This electron delocalization 
may also promote binding to the heme iron and enhance inhibitor affinity, as it is 
reported about several Δ16 unsaturated C-17 heterocyclic steroidal compounds [5, 17, 
24]. the 17-picolinyliden-androst-4-en-3-on compound (6) exerted effective inhibi-
tion towards both the 17α-hydroxylase and C17,20-lyase activities of the P45017α. 
our results demonstrate that the presented methods provide feasible ways for 
determination of activities and inhibitions of 17α -hydroxylase and C17,20-lyase of the 
P45017α. Our findings indicate that steroidal 17-picolinylidene compounds may pos-
sibly be promising target molecules of P45017α inhibitor research. synthesis of further 
17-picolinylidene steroids and investigations to explore presumed antiandrogenic 
properties of the new compounds are to be performed.
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